Zepp Health (NYSE:ZEPP – Get Free Report) and Evaxion A/S (NASDAQ:EVAX – Get Free Report) are both small-cap consumer discretionary companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, dividends, earnings, institutional ownership and risk.
Profitability
This table compares Zepp Health and Evaxion A/S’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Zepp Health | -14.70% | -15.64% | -6.03% |
| Evaxion A/S | N/A | -73.56% | -37.45% |
Analyst Recommendations
This is a breakdown of current ratings for Zepp Health and Evaxion A/S, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Zepp Health | 1 | 0 | 1 | 0 | 2.00 |
| Evaxion A/S | 1 | 0 | 5 | 0 | 2.67 |
Valuation & Earnings
This table compares Zepp Health and Evaxion A/S”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Zepp Health | $258.90 million | 0.26 | -$40.07 million | ($2.52) | -1.82 |
| Evaxion A/S | $7.53 million | 3.27 | -$7.71 million | ($1.47) | -2.01 |
Evaxion A/S has lower revenue, but higher earnings than Zepp Health. Evaxion A/S is trading at a lower price-to-earnings ratio than Zepp Health, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
52.6% of Zepp Health shares are owned by institutional investors. Comparatively, 11.0% of Evaxion A/S shares are owned by institutional investors. 36.0% of Zepp Health shares are owned by company insiders. Comparatively, 41.6% of Evaxion A/S shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Volatility & Risk
Zepp Health has a beta of 1.86, suggesting that its stock price is 86% more volatile than the S&P 500. Comparatively, Evaxion A/S has a beta of 0.29, suggesting that its stock price is 71% less volatile than the S&P 500.
About Zepp Health
Zepp Health Corporation operates as a smart wearable and health technology company worldwide. The company operates in two segments: Self-Branded Products and Others, and Xiaomi Wearable Products. It empowers users to live lives by optimizing health, fitness, and wellness journeys through its consumer brands, Amazfit, Zepp Clarity, and Zepp Aura. The company through its proprietary Zepp Digital Management Platform, which includes the Zepp OS, AI chips, biometric sensors, and data algorithms, delivers cloud-based 24/7 actionable insights and guidance to help users attain wellness goals. The company offers smart bands, watches, modules, and scales; and associated accessories, smart hearable products, sportswear, home fitness equipment, home appliances, and smart watch accessories. It also provides charts and graphs to display analysis of the activity and biometric data collected from users through its Zepp Life and Zepp mobile apps. It offers its products under the Amazfit and Zepp brand names in approximately 90 countries. The company was formerly known as Huami Corporation and changed its name to Zepp Health Corporation in February 2021. Zepp Health Corporation was founded in 2013 and is headquartered in Hefei, the People's Republic of China.
About Evaxion A/S
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.
Receive News & Ratings for Zepp Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zepp Health and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.jpg){kind=logo}
